Demand for minimally invasive surgical procedures results in service expansion into Ohio, Texas, Michigan, New York, and New Jersey

Miami, FL – October 13, 2021 – TissueTech, Inc., a pioneer in the clinical application of cryopreserved human birth tissue allografts to treat ocular surface disease and disorders, chronic wounds, and musculoskeletal conditions, announced today that they had completed a new round of hiring for their two commercial subsidiaries Bio-Tissue and Amniox Medical. The recently hired sales representatives and associate sales representatives enrolled in TissueTech’s newly created mentorship program will support organizational growth under the oversight of Brandon Caraway, Vice President of Sales.

TissueTech leadership remains optimistic about its trajectory and has expanded its sales force accordingly. This latest round of hiring substantiates a nationwide trend towards moving many minimally invasive surgical procedures to outpatient settings, as published in a study conducted by KNG Health Consulting. This study showed that in the coming years, between 2019 to 2028, the projected total Medicare savings generated by ambulatory surgery centers could be $73.4 billion.1

Amy Tseng, President and Chief Executive Officer of TissueTech, cites the advent of value-based care that emphasizes healthcare cost-containment as a factor contributing to the organization’s recent expansion and a subsequent need to grow its sales force. “Our human birth tissue-engineered products are ideally suited for the outpatient environment. During the past 18 months, we have seen an exponential rise in the number of providers adopting our platform technology as a viable treatment to facilitate regenerative healing.”

About TissueTech, Inc.

TissueTech, Inc. is an emerging biotechnology company and leader in regenerative medicine using human birth tissue. TissueTech’s pioneering amniotic membrane products are processed using its proprietary CRYOTEK® cryopreservation technology, designed to retain the tissue’s structural and functional integrity. Today, TissueTech is breaking new ground with multiple Investigational New Drug clinical trials underway as the company pursues 351 biologics’ approval for products to treat patients’ unmet clinical needs. TissueTech is committed to empowering healthcare professionals with solutions to deliver optimal patient outcomes by fostering innovation through evidence-based science. Since its inception, clinicians have performed over 600,000 human implants with its products and published over 380 peer-reviewed studies supporting TissueTech’s platform technology. Learn more at https://tissuetech.com.

About Amniox Medical, Inc.

Amniox Medical, Inc. is a TissueTech, Inc. company. It is focused on harnessing the unique power of human birth tissue to support regenerative healing and functional recovery in surgical, chronic wound, and musculoskeletal applications. The Amniox family of cryopreserved amniotic membrane products are processed using its proprietary CRYOTEK® technology to retain the birth tissue’s structural and functional integrity. Amniox is committed to facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives. Connect with Amniox on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.

About Bio-Tissue, Inc.

Bio-Tissue, Inc. is a TissueTech, Inc. company. It is pioneering the clinical application of human birth tissue to promote regenerative healing for ocular surface disease and disorders. The Bio-Tissue portfolio of cryopreserved amniotic membrane products are processed using its proprietary CRYOTEK® technology to retain the birth tissue’s structural and functional integrity. As a leader in clinical research, Bio-Tissue has been facilitating optimal clinical outcomes, solving previously unmet clinical and patient needs, and positively impacting patients’ lives since 1997. Connect with Bio-Tissue on our Website, Physician Portal, Facebook, LinkedIn, Instagram, and Twitter, or through your local sales professional.

 

  1. Medicare Cost Savings Report_Draft_9(10-5-20) (higherlogicdownload.s3.amazonaws.com)